



THE UNIVERSITY *of* EDINBURGH

Edinburgh Research Explorer

DNA methylation reprogramming in cancer

Citation for published version:

Reddington, JP, Sproul, D & Meehan, R 2014, 'DNA methylation reprogramming in cancer: Does it act by re-configuring the binding landscape of Polycomb repressive complexes?' *BioEssays*, vol. 36, no. 2. DOI: 10.1002/bies.201300130

Digital Object Identifier (DOI):

[10.1002/bies.201300130](https://doi.org/10.1002/bies.201300130)

Link:

[Link to publication record in Edinburgh Research Explorer](#)

Document Version:

Publisher's PDF, also known as Version of record

Published In:

BioEssays

Publisher Rights Statement:

© 2014 The Authors. Bioessays published by WILEY Periodicals, Inc.

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

General rights

Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy

The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.





DNA methylation reprogramming in cancer: Does it act by re-configuring the binding landscape of Polycomb repressive complexes?

James P. Reddington[†], Duncan Sproul and Richard R. Meehan*

DNA methylation is a repressive epigenetic mark vital for normal development. Recent studies have uncovered an unexpected role for the DNA methylome in ensuring the correct targeting of the Polycomb repressive complexes throughout the genome. Here, we discuss the implications of these findings for cancer, where DNA methylation patterns are widely reprogrammed. We speculate that cancer-associated reprogramming of the DNA methylome leads to an altered Polycomb binding landscape, influencing gene expression by multiple modes. As the Polycomb system is responsible for the regulation of genes with key roles in cell fate decisions and cell cycle regulation, DNA methylation induced Polycomb mis-targeting could directly drive carcinogenesis and disease progression.

Keywords:

■ cancer epigenetics; DNA methylation; epigenomics; H3K27me3; Polycomb; reprogramming

Introduction

Epigenetic systems modulate the interpretation of the information contained in genomes by regulating DNA

dependent processes. Many different epigenetic pathways act in mammalian cells and recent work has highlighted extensive interactions between them [1]. The epigenome is frequently

altered in cancer, and there is evidence to suggest that interactions between distinct epigenetic mechanisms are important drivers in this process [2, 3]. Identifying the causes of epigenetic reprogramming in cancer and understanding its consequences for disease pathology are key challenges in molecular biology.

DNA methylation and the Polycomb repression system are two epigenetic pathways that play key roles in cancer formation and progression. Here, we focus on recent evidence that links DNA methylation to the genomic targeting of Polycomb repressive complexes (PRCs), the effectors of the Polycomb system. In light of this evidence, we discuss how widespread reprogramming of DNA methylation patterns in cancer could drive the relocation of PRCs on chromatin, and contribute to carcinogenesis through alterations in gene expression.

The cancer DNA methylome: How does it change and what are the consequences?

Mammalian genomes exhibit widespread DNA methylation that is acquired during early development [4]. DNA methylation is laid down and maintained by the DNA methyltransferases, DNMT1, DNMT3A, and DNMT3B,

DOI 10.1002/bies.201300130

MRC Human Genetics Unit, MRC IGMM, University of Edinburgh, Edinburgh, United Kingdom

[†]Present address: Genome Biology Unit, European Molecular Biology Laboratory, Heidelberg, Germany.

*Corresponding author:

Richard R. Meehan
E-mail: richard.meehan@igmm.ed.ac.uk

Abbreviations:

CGI, CpG island; **CpG**, cytosine followed immediately by a guanine in the 5' to 3' direction; **ES**, embryonic stem (cells); **H3K27me3**, tri-methylation of lysine 27 on histone H3; **hmC**, 5'-hydroxymethylcytosine; **LINE**, long interspersed nuclear element; **mC**, 5'-methylcytosine; **MEFs**, mouse embryonic fibroblasts; **PMDs**, partially (DNA) methylated domains; **PRC**, Polycomb repressive complex; **PRC1**, Polycomb repressive complex 1; **PRC2**, Polycomb repressive complex 2.




Figure 1. Reprogramming of DNA methylation patterns in cancer. Frequently observed changes to the DNA methylome in cancer are depicted for a portion of a hypothetical genome. CpG dinucleotides are depicted as open (unmethylated cytosine) or filled (5-methylcytosine). In healthy somatic cells (“Normal DNA methylome”) the background level of CpG methylation throughout the bulk genome is high, while CGIs are infrequently methylated [5, 28]. In cancer, CGIs frequently become hypermethylated (red bars and boxes), and CpG methylation is reduced across large genomic domains (blue bars and boxes) [14, 16]. Focal CGI hypermethylation frequently occurs within larger hypomethylated domains [16]. Only unmethylated and 5-methylcytosine are shown for simplicity. CGI, CpG island.

and generally occurs at cytosines in a 5'-CG-3' (CpG) dinucleotide context [4]. This pervasively methylated landscape is interspersed with short hypomethylated regions, the best described of which are CpG islands (CGIs) [5] (Fig. 1). Enzymes of the TET family can oxidize methylated cytosine (mC) to generate further modified bases, of which 5'-hydroxymethylcytosine (hmC) is the most abundant [6]. The oxidation of mC by TET enzymes is proposed to be the first step in DNA demethylation pathways but stable levels of hmC of unknown significance are found in the bodies of active genes [6].

DNA methylation is classically implicated in gene regulation at promoters, where it is proposed to repress transcription initiation by attenuating the binding of transcription factors, and recruiting repressor complexes through the attraction of methyl-CpG binding proteins [7]. CGIs rarely become methylated during normal development and most are likely to function as gene promoters [5]. However, the methylation of some CGIs plays a vital role in genomic imprinting,

the inactivation of one copy of the X chromosome in female cells and the regulation of some tissue-specific genes [4].

Cancer DNA methylomes exhibit focal hypermethylation and widespread hypomethylation

Two radical differences exist between normal mammalian DNA methylation landscapes and those found in cancer: many CGIs become aberrantly hypermethylated in cancerous cells, and large amounts of DNA methylation are lost from other genomic regions [8] (Fig. 1). Interestingly, the Polycomb system has been suggested to play an instructive role in the hypermethylation of promoter DNA in cancer, as genes that are subject to promoter hypermethylation are frequently marked by PRC2-deposited H3K27me3 in early development [2, 9, 10]. Hypermethylation of CGI promoters was

classically believed to directly drive carcinogenesis by silencing tumor suppressor genes [8]. Studies using genomic profiling technologies have conclusively demonstrated that this is not the case for the vast majority of aberrantly hypermethylated genes, as they are already silenced in the corresponding normal cells that give rise to cancer [11–13]. However, these observations do not rule out the possibility that rare driver genes are directly silenced by aberrant CGI hypermethylation [11].

In addition to aberrant CGI hypermethylation, cancer genomes exhibit widespread loss of DNA methylation (Fig. 1). Work over many years suggested that loss of methylation occurs primarily in the repetitive portion of the genome, in particular satellite repeats and LINE-1 retrotransposons [14]. This view has been radically altered by the application of whole genome bisulfite sequencing technology to cancer, which revealed that DNA methylation is lost from megabase-scale genomic domains [3, 15, 16]. Although these domains are enriched in LINE-1 elements, those lying outside of these domains do not become hypomethylated, suggesting that the loss of methylation is not specific to retrotransposons [14, 15]. Hypomethylated domains often overlap with other features of mammalian genomes, particularly lamin-associated domains, which associate with the nuclear lamina at the periphery of the nucleus [14, 16]. However, it is currently unclear whether the nuclear lamina is mechanistically

connected to the loss of methylation in cancer.

Experiments in transgenic animals have demonstrated that genomic hypomethylation can either inhibit or promote carcinogenesis depending on the cellular context [17, 18]. Loss of DNA methylation causes genomic instability in transgenic animals [17], cultured cells [19], and in patients with Immunodeficiency–Centromeric instability–Facial anomalies (ICF) syndrome, which is caused by mutations in *DNMT3B* [20]. Hypomethylation may also promote cancer by potentiating the activation and transposition of LINE-1 elements [21]. Such activation can potentially directly disrupt genes through transposition into their vicinity [22, 23] or because transcription from LINE-1 promoters can affect neighboring genes [24, 25].

Despite the application of the latest genomic approaches to cancer DNA methylomes, we still have a limited understanding of the causes of DNA methylation reprogramming and its impact on cancer phenotypes. The picture is complicated by heterogeneity caused by differences in cellular origin or stochastic clonal evolution [12]. Furthermore, recent studies seeking to understand the role of DNA methylation in normal cells have uncovered previously unappreciated functions of the DNA methylome in gene regulation, highlighting the diverse ways that this epigenetic mark is utilized in mammalian genomes [1].

A new role for DNA methylation in shaping the Polycomb landscape

In addition to methyl-CpG binding proteins, we now know that an eclectic variety of proteins exhibit DNA methylation-modulated binding to chromatin [1, 26]. Many of these possess histone-modification activity, and are involved in setting up diverse aspects of chromatin organization, highlighting roles for DNA methylation outside of promoter proximal regions [1]. This raises the possibility that the effects of an altered DNA methylome in cancer could be more widespread than currently appreciated.

Box 1 – Polycomb repressive complexes and their genomic targeting

The Polycomb system is a highly conserved epigenetic mechanism that contributes to the stable repression of thousands of target genes outside of their normal expression domains [40]. The system comprises the coordinated action of several multi-protein complexes that associate with chromatin, many of which chemically modify histone proteins through the deposition of histone marks. The Polycomb Repressive Complex 2 (PRC2) catalyses tri-methylation of lysine 27 on histone H3 (H3K27me₃), a signature of repression mediated by this complex. A subset of Polycomb repressive complex 1 (PRC1) binds to the H3K27me₃ mark and catalyses the mono-ubiquitination of histone H2A. A major question in Polycomb research is how PRCs are targeted to the correct genomic compartments [40]. Polycomb targeting is best understood in the fruit fly, where PRCs are recruited to specific sequence elements called Polycomb response elements (PREs) by combinations of sequence-specific binding proteins [40]. PRC recruitment is far less understood in mammals and is thought to result from the interaction between multiple DNA sequence features and chromatin structure [40]. For example, CGIs have been linked to the recruitment of Polycomb complexes [36], but the mechanism of recruitment to these elements remains unclear.

DNA methylation attenuates PRC2 binding to chromatin

It has emerged that DNA methylation plays an unexpected role in restricting the genomic targeting of Polycomb repressor complexes (PRCs) (see Box 1 for an overview of Polycomb repressive complexes and their targeting). While DNA methylation and Polycomb were once considered to be two independent and complementary pathways of transcriptional repression, it is now conceivable that direct cross talk occurs between them. Epigenome profiling experiments showed that high levels of DNA methylation and H3K27me₃ are rarely found at the same loci in mammalian genomes, suggesting that the presence of one mark is antagonistic to the other [27–32]. This relationship is most prominent at CGIs [31], but can be observed to a lesser extent at large partially methylated domains (PMDs) in cultured cells [28, 30]. Exclusivity between the two marks is exemplified by the imprinted *Rasgrf1* locus where one allele is marked by DNA methylation and the other by H3K27me₃ [33].

Recent studies have addressed the cause-consequence relationships involved in establishing these patterns

by perturbing either DNA methylation or H3K27me₃ and asking what happens to the other mark. In multiple organisms and experimental systems, the removal of DNA methylation has a profound influence on the distribution of the H3K27me₃ mark throughout the genome [29, 31, 33–37]. Crucially, removal of DNA methylation results in accumulation of the PRC2 complex and H3K27me₃ in illegitimate genomic locations that were previously DNA methylated [31, 34, 35], suggesting that dense DNA methylation is capable of attenuating PRC2 binding to chromatin. This is supported by *in vitro* experiments demonstrating reduced PRC2 occupancy and activity on DNA methylated chromatin templates [26, 34]. In addition, TET1 is required for a significant proportion of PRC targeting in mouse ES cells, connecting this putative demethylation pathway to PRC recruitment [38]. In contrast, when PRC2 components are removed only modest changes in DNA methylation are observed [39], suggesting that the H3K27me₃ mark does not have a similar reciprocal effect on the placement of DNA methylation in non-transformed cells.

While the majority of studies have focused on the influence of DNA methylation on the PRC2 complex, it is likely that PRC1 localization is also affected. Canonically, PRC1 is

recruited to genomic loci by the H3K27me3 mark laid down by PRC2 [40], so restriction of PRC2 binding by DNA methylation would be expected to also affect PRC1 recruitment. A recent study has also detailed a non-canonical PRC1 recruitment pathway mediated by the KDM2B protein, which contains an unmethylated CpG binding CXXC domain [41].

The DNA methylome is required for correct PRC2-mediated gene repression

As PRCs are involved in transcriptional repression, their redistribution upon loss of DNA methylation can have significant effects on the transcriptome. For example, in *Dnmt3a* mutant neural stem cells, levels of DNA methylation are reduced within the body of some actively transcribed genes, leading to PRC2 binding and repression of their transcription [34]. Removal of most DNA methylation from mouse embryonic fibroblasts (MEFs) leads to a variety of transcriptional consequences connected to PRC redistribution [35]. Genes lying within regions of the genome that accumulate H3K27me3 in DNA methylation mutants are often transcriptionally down-regulated, consistent with de novo repression by PRC2 within these regions [35]. Surprisingly, many normal PRC2 target genes are de-repressed in DNA methylation mutants, concomitant with loss of H3K27me3 from their promoter regions [35]. Importantly, these genes are associated with unmethylated CGI promoters in wild type cells [35], meaning that DNA methylation would not normally be implicated in their regulation. The loss of H3K27me3 observed here could be explained by dilution of a limited amount of PRC2, due to the increased binding of this complex to numerous intergenic sites uncovered by loss of DNA methylation [35].

Many interesting questions remain concerning the relationship between DNA methylation and the Polycomb system and its implications for genome regulation. Despite the fact that in vitro experiments have suggested that PRC2 is able to directly read CpG methylation states [26, 34], the molecular mechanism

underlying this cross talk is currently furtive. One important implication of these observations is that reprogramming of DNA methylation patterns in cancer could trigger mis-regulation of transcriptional programs through subsequent redistribution of the repressive activity of PRCs.

Do DNA methylation changes drive Polycomb redistribution in cancer?

In addition to changes in the DNA methylome, H3K27me3 patterns are subject to reprogramming in cancer cells [32, 42]. Studies have documented correlated changes in DNA methylation and H3K27me3 in cancer, raising the possibility that at least some of the redistribution of these two marks is causally linked [3, 43].

Based on frequently observed changes to the DNA methylome in cancer, multiple putative effects on PRC-mediated gene regulation can be envisaged (Fig. 2). One such pathway is epigenetic switching, where DNA methylation replaces PRCs at CGIs in cancer [43] (Fig. 2A). Both studies of individual genes and epigenomic profiling have shown that promoter CGIs that are subject to aberrant hypermethylation in cancer are frequently marked by PRCs during development [2, 9, 10]. In prostate cancer, developmentally important CGI genes silenced by PRC2 in normal prostate cells acquire DNA methylation concomitant with loss of their PRC2 marks [43]. Because these genes are normally silent in the tissue that gives rise to cancer, this epigenetic switch would not be expected to cause de novo repression. However, as repression by DNA methylation is more stable than PRC-mediated repression, this switch could significantly reduce epigenetic plasticity by preventing the future activation of genes in response to external stimuli, potentially blocking cellular differentiation [11].

Genomic hypomethylation in cancer is also likely to impact on the transcriptome. The de novo formation or exacerbation of PMDs in cancer, due to the processes underlying hypomethylation, could uncover binding sites for

PRC2, allowing the formation of new H3K27me3 domains and causing the repression of multiple adjacent genes (Fig. 2B) [3]. The H3K27me3 modification is thought to be propagated by the binding of the PRC2 component EED to H3K27me3 resulting in spreading of PRCs unless boundaries are applied [44]. DNA methylation surrounding a PRC2-bound locus could act locally to prevent spreading of H3K27me3 into neighboring regions (Fig. 2C). Proximity to existing H3K27me3 marked loci could, therefore, play an important role in determining whether a gene becomes repressed by PRC recruitment following loss of DNA methylation.

In addition to de novo gene repression, loss of PRC restriction by DNA methylation in cancer could paradoxically result in the de-repression of Polycomb-target genes, as observed in DNA methylation mutant MEFs [35] (Fig. 2D). In support of this hypothesis, loss of H3K27me3 and de-repression of PRC targets has been reported in cancer [45, 46], but it is currently unclear if these alterations are driven by cancer-associated hypomethylation. Such a pathway is most probable in cancers that exhibit the largest degree of DNA hypomethylation. However, the picture is likely to be complicated by the elevated expression, and frequent mutation, of Polycomb components in certain cancers [40, 42]. It has also been suggested that the relationship between DNA methylation and PRC2 is fundamentally different in normal and transformed cells, adding a further layer of complexity to this problem [29]. The targets of PRCs include a large number of genes with key functions in cell lineage decisions and the regulation of the cell cycle [40]. The mis-regulation of these genes could in theory have a major impact on the formation and progression of cancer, providing the impetus for further research in this area.

Conclusions and prospects

In differentiated cells part of the barrier to transformation is precise partitioning of the genome into active and repressed domains; epigenetic reorganization of





Figure 2. Putative pathways for gene mis-regulation in cancer. Previously described and hypothetical changes to PRC2-mediated gene repression in cancer in response to DNA methylation redistribution. **A:** DNA hypermethylation of a PRC2-bound promoter CGI in cancer causes loss of PRC2 and H3K27me3 [43]. **B:** The loss of DNA methylation across large genomic domains could allow PRC2 to form large blocks of H3K27me3 modified chromatin de novo, leading to the silencing of multiple adjacent genes [3]. **C:** Loss of DNA methylation surrounding H3K27me3 marked regions allows spreading of PRC2 occupancy into adjacent chromatin and de novo gene repression. **D:** Widespread loss of DNA methylation throughout the cancer genome allows PRC2 to occupy a large number of new sites, distributing the complex over a larger proportion of the genome. As a result, PRC2 occupancy is reduced at normal PRC2-target genes, leading to de-repression of a subset of them that are particularly sensitive to PRC2 reduction [35]. PRC2, Polycomb repressive complex 2.

these domains is a feature of both cellular and cancer reprogramming. Understanding the cause and functional impact of epigenetic reprogramming is a major goal of both basic and clinical research. The action of PRCs is fundamentally important to many types of cancers as exemplified by the recurrent mutations of PRC components uncovered by cancer re-sequencing studies [14]. Reprogramming of the DNA methylome in cancer could drive further epigenetic instability in an unexpected

way, by reshaping the PRC binding landscape.

The functional consequences of DNA methylation mediated PRC redistribution as described here are also likely to be important in other biological systems. Large-scale hypomethylation and the formation of PMDs are now known to be a feature of aging cells [47] and of some normal cell populations including the placenta [48] and mature B-cells [49].

In cancer, this mechanism could potentially impact genome regulation in many ways, leading to a transcriptome that facilitates cancer formation, plasticity, and progression, or influences how cancers respond to therapy. We are just beginning to comprehend the epigenetic heterogeneity that exists in cancer [14]. Changes to the DNA methylome driven by a stochastic or step-wise process could offer a substrate for cellular Darwinism [14, 50], providing intermediates with favorable patterns of gene expression that arise due to altered H3K27me3 targeting. Future studies should concentrate on dissecting the cause-consequence relationships involved, and exploring potential points of therapeutic intervention.

Acknowledgments

The Meehan lab acknowledges funding from the Medical Research Council, IMI-MARCAR and the BBSRC. The Sproul lab is funded by the University of Edinburgh and Breast Cancer Campaign. The authors apologize to any colleagues whose work was not properly cited due to space constraints.

The authors have declared no conflict of interest.

References

- Reddington JP, Pennings S, Meehan RR. 2013. Non-canonical functions of the DNA methylome in gene regulation. *Biochem J* **451**: 13–23.
- Schlesinger Y, Straussman R, Keshet I, Farkash S, et al. 2007. Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer. *Nat Genet* **39**: 232–6.
- Hon GC, Hawkins RD, Caballero OL, Lo C, et al. 2012. Global DNA hypomethylation coupled to repressive chromatin domain formation and gene silencing in breast cancer. *Genome Res* **22**: 246–58.
- Cedar H, Bergman Y. 2012. Programming of DNA methylation patterns. *Annu Rev Biochem* **81**: 97–117.
- Deaton AM, Bird A. 2011. CpG islands and the regulation of transcription. *Genes Dev* **25**: 1010–22.
- Branco MR, Ficiz G, Reik W. 2012. Uncovering the role of 5-hydroxymethylcytosine in the epigenome. *Nat Rev Genet* **13**: 7–13.
- Klose RJ, Bird AP. 2006. Genomic DNA methylation: the mark and its mediators. *Trends Biochem Sci* **31**: 89–97.
- Feinberg AP, Tycko B. 2004. The history of cancer epigenetics. *Nat Rev Cancer* **4**: 143–53.
- Ohm JE, McGarvey KM, Yu X, Cheng L, et al. 2007. A stem cell-like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing. *Nat Genet* **39**: 237–42.
- Widschwendter M, Fiegl H, Egle D, Mueller-Holzner E, et al. 2007. Epigenetic stem cell signature in cancer. *Nat Genet* **39**: 157–8.
- Sproul D, Meehan RR. 2013. Genomic insights into cancer-associated aberrant CpG island hypermethylation. *Brief Funct Genomics* **12**: 174–90.
- Sproul D, Nestor C, Culley J, Dickson JH, et al. 2011. Transcriptionally repressed genes become aberrantly methylated and distinguish tumors of different lineages in breast cancer. *Proc Natl Acad Sci USA* **108**: 4364–9.
- Keshet I, Schlesinger Y, Farkash S, Rand E, et al. 2006. Evidence for an instructive mechanism of de novo methylation in cancer cells. *Nat Genet* **38**: 149–53.
- Timp W, Feinberg AP. 2013. Cancer as a dysregulated epigenome allowing cellular growth advantage at the expense of the host. *Nat Rev Cancer* **13**: 497–510.
- Hansen KD, Timp W, Bravo HC, Sabunciyan S, et al. 2011. Increased methylation variation in epigenetic domains across cancer types. *Nat Genet* **43**: 768–75.
- Berman BP, Weisenberger DJ, Aman JF, Hinoue T, et al. 2012. Regions of focal DNA hypermethylation and long-range hypomethylation in colorectal cancer coincide with nuclear lamina-associated domains. *Nat Genet* **44**: 40–6.
- Gaudet F, Hodgson JG, Eden A, Jackson-Grusby L, et al. 2003. Induction of tumors in mice by genomic hypomethylation. *Science* **300**: 489–92.
- Yamada Y, Jackson-Grusby L, Linhart H, Meissner A, et al. 2005. Opposing effects of DNA hypomethylation on intestinal and liver carcinogenesis. *Proc Natl Acad Sci USA* **102**: 13580–5.
- Hernandez R, Frady A, Zhang XY, Varela M, et al. 1997. Preferential induction of chromosome 1 multibranching figures and whole-arm deletions in a human pro-B cell line treated with 5-azacytidine or 5-azadeoxycytidine. *Cytogenet Cell Genet* **76**: 196–201.
- Xu GL, Bestor TH, Bourc'his D, Hsieh CL, et al. 1999. Chromosome instability and immunodeficiency syndrome caused by mutations in a DNA methyltransferase gene. *Nature* **402**: 187–91.
- Rodic N, Burns KH. 2013. Long interspersed element-1 (LINE-1): passenger or driver in human neoplasms? *PLoS Genet* **9**: e1003402.
- Lee E, Iskov R, Yang L, Gokcumen O, et al. 2012. Landscape of somatic retrotransposition in human cancers. *Science* **337**: 967–71.
- Shukla R, Upton KR, Munoz-Lopez M, Gerhardt DJ, et al. 2013. Endogenous retrotransposition activates oncogenic pathways in hepatocellular carcinoma. *Cell* **153**: 101–11.
- Wolff EM, Byun HM, Han HF, Sharma S, et al. 2010. Hypomethylation of a LINE-1 promoter activates an alternate transcript of the MET oncogene in bladders with cancer. *PLoS Genet* **6**: e1000917.
- Cruickshanks HA, Vafadar-Isfahani N, Dunican DS, Lee A, et al. 2013. Expression of a large LINE-1-driven antisense RNA is linked to epigenetic silencing of the metastasis suppressor gene TFPI-2 in cancer. *Nucleic Acids Res* **41**: 6857–9.
- Bartke T, Vermeulen M, Xhemalce B, Robson SC, et al. 2010. Nucleosome-interacting proteins regulated by DNA and histone methylation. *Cell* **143**: 470–84.
- Meissner A, Mikkelsen TS, Gu H, Wernig M, et al. 2008. Genome-scale DNA methylation maps of pluripotent and differentiated cells. *Nature* **454**: 766–70.
- Lister R, Pelizzola M, Dowen RH, Hawkins RD, et al. 2009. Human DNA methylomes at base resolution show widespread epigenomic differences. *Nature* **462**: 315–22.
- Murphy PJ, Cipriany BR, Wallin CB, Ju CY, et al. 2013. Single-molecule analysis of combinatorial epigenomic states in normal and tumor cells. *Proc Natl Acad Sci USA* **110**: 7772–7.
- Hawkins RD, Hon GC, Lee LK, Ngo Q, et al. 2010. Distinct epigenomic landscapes of pluripotent and lineage-committed human cells. *Cell Stem Cell* **6**: 479–91.
- Brinkman AB, Gu H, Bartels SJ, Zhang Y, et al. 2012. Sequential ChIP-bisulfite sequencing enables direct genome-scale investigation of chromatin and DNA methylation cross-talk. *Genome Res* **22**: 1128–38.
- Kondo Y, Shen L, Cheng AS, Ahmed S, et al. 2008. Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation. *Nat Genet* **40**: 741–50.
- Lindroth AM, Park YJ, McLean CM, Dokshin GA, et al. 2008. Antagonism between DNA and H3K27 methylation at the imprinted Rasgrf1 locus. *PLoS Genet* **4**: e1000145.
- Wu H, Coskun V, Tao J, Xie W, et al. 2010. Dnmt3a-dependent nonpromoter DNA methylation facilitates transcription of neurogenic genes. *Science* **329**: 444–8.
- Reddington JP, Perricone SM, Nestor CE, Reichmann J, et al. 2013. Redistribution of H3K27me3 upon DNA hypomethylation results in de-repression of Polycomb target genes. *Genome Biol* **14**: R25.
- Lynch MD, Smith AJ, De Gobbi M, Flenley M, et al. 2012. An interspecies analysis reveals a key role for unmethylated CpG dinucleotides in vertebrate Polycomb complex recruitment. *EMBO J* **31**: 317–29.
- Deleris A, Stroud H, Bernatavichute Y, Johnson E, et al. 2012. Loss of the DNA methyltransferase MET1 induces H3K9 hypermethylation at PcG target genes and redistribution of H3K27 trimethylation to transposons in *Arabidopsis thaliana*. *PLoS Genet* **8**: e1003062.
- Williams K, Christensen J, Pedersen MT, Johansen JV, et al. 2011. TET1 and hydroxymethylcytosine in transcription and DNA methylation fidelity. *Nature* **473**: 343–8.

39. **Hagarman JA, Motley MP, Kristjansdottir K, Soloway PD.** 2013. Coordinate regulation of DNA methylation and H3K27me3 in mouse embryonic stem cells. *PLoS One* **8**: e53880.
40. **Simon JA, Kingston RE.** 2013. Occupying chromatin: Polycomb mechanisms for getting to genomic targets, stopping transcriptional traffic, and staying put. *Mol Cell* **49**: 808–24.
41. **Farcas AM, Blackledge NP, Sudbery I, Long HK,** et al. 2012. KDM2B links the Polycomb repressive complex 1 (PRC1) to recognition of CpG islands. *eLife* **1**: e00205.
42. **Cheng AS, Lau SS, Chen Y, Kondo Y,** et al. 2011. EZH2-mediated concordant repression of Wnt antagonists promotes beta-catenin-dependent hepatocarcinogenesis. *Cancer Res* **71**: 4028–39.
43. **Gal-Yam EN, Egger G, Iniguez L, Holster H,** et al. 2008. Frequent switching of Polycomb repressive marks and DNA hypermethylation in the PC3 prostate cancer cell line. *Proc Natl Acad Sci USA* **105**: 12979–84.
44. **Margueron R, Justin N, Ohno K, Sharpe ML,** et al. 2009. Role of the polycomb protein EED in the propagation of repressive histone marks. *Nature* **461**: 762–7.
45. **Rheinbay E, Suva ML, Gillespie SM, Wakimoto H,** et al. 2013. An aberrant transcription factor network essential for Wnt signaling and stem cell maintenance in glioblastoma. *Cell Rep* **3**: 1567–79.
46. **Bert SA, Robinson MD, Strbenac D, Statham AL,** et al. 2013. Regional activation of the cancer genome by long-range epigenetic remodeling. *Cancer Cell* **23**: 9–22.
47. **Heyn H, Li N, Ferreira HJ, Moran S,** et al. 2012. Distinct DNA methylomes of newborns and centenarians. *Proc Natl Acad Sci USA* **109**: 10522–7.
48. **Schroeder DI, Blair JD, Lott P, Yu HO,** et al. 2013. The human placenta methylome. *Proc Natl Acad Sci USA* **110**: 6037–42.
49. **Kulis M, Heath S, Bibikova M, Queiros AC,** et al. 2012. Epigenomic analysis detects widespread gene-body DNA hypomethylation in chronic lymphocytic leukemia. *Nat Genet* **44**: 1236–42.
50. **Issa JP.** 2011. Epigenetic variation and cellular Darwinism. *Nat Genet* **43**: 724–6.